多发性骨髓瘤采集物可测量残留病与生物学特征、缓解深度及生存的相关性
该回顾性研究分析了422例接受自体干细胞移植的多发性骨髓瘤患者,采用8色流式细胞术评估采集物可测量残留病(aMRD)。10%患者aMRD阳性,与采集前缓解差于VGPR及骨髓MRD阳性相关,且aMRD阳性者移植后完全缓解率和骨髓MRD阴性率更低,无进展生存更短,并独立预测早期复发。
要点
- 采集物aMRD阳性率10%,与t(11;14)频率较高相关。
- 采集前缓解差于VGPR者aMRD阳性风险高6.6倍,骨髓MRD阴性者无aMRD阳性。
- aMRD阳性独立预测早期复发(OR 9.75)并缩短无进展生存(HR 1.7)。
核心结论
- aMRD阳性可能是识别治疗反应欠佳、反映骨髓MRD持续并预测不良结局的早期生物标志物。
研究设计与样本
- 回顾性分析2005至2023年萨拉曼卡大学医院接受ASCT的422例MM患者,全部用8色流式细胞术评估aMRD。
主要发现
- 45例(10%)aMRD阳性,377例(90%)aMRD阴性,基线特征相似,但aMRD阳性者t(11;14)频率更高。
- 采集前缓解差于VGPR者aMRD阳性可能性高6倍(OR 6.6,p=0.006),采集前bmMRD阴性者无aMRD阳性。
- ASCT后aMRD阳性者完全缓解率和bmMRD阴性率更低,无进展生存更短(HR 1.7,p=0.006)。
- aMRD阳性是早期复发的独立预测因素(OR 9.75,p=0.007)。
临床怎么用
- 对采集前缓解欠佳或骨髓MRD阳性患者,可考虑检测采集物aMRD以识别高危亚群。
局限性
- 回顾性单中心研究,aMRD检测采用8色流式细胞术,结论需前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
While measurable residual disease (MRD) in bone marrow (bmMRD) is a validated surrogate biomarker in multiple myeloma (MM), the clinical relevance of MRD in the apheresis product (aMRD) remains unclear. We retrospectively analysed 422 MM patients who underwent autologous stem cell transplantation (ASCT) between 2005 and 2023 at the University Hospital of Salamanca, all evaluated for aMRD by 8-colour flow cytometry. Overall, 45 patients (10%) were aMRD+ve and 377 (90%) were aMRD-ve, with similar baseline characteristics except for a higher frequency of t(11;14) in aMRD+ve cases. Patients with responses worse than a very good partial response before apheresis were six times more likely to be aMRD+ve (odds ratio [OR] 6.6, p = 0.006), and notably, no patients with bmMRD-ve status prior to apheresis were aMRD+ve. After ASCT, patients with aMRD+ve exhibited lower rates of complete response and bmMRD-ve than patients with aMRD-ve, leading to a shorter progression-free survival (hazard ratio 1.7, p = 0.006), and aMRD+ve status was identified as an independent predictor of early relapse (OR 9.75, p = 0.007). These findings may suggest that aMRD+ve serves as a critical early biomarker to identify suboptimal treatment responses, reflecting bmMRD persistence and predicting inferior clinical outcomes.
引用
- Puertas B, Padilla I, Alejo E, et al. Measurable residual disease assessment in apheresis product from multiple myeloma patients: Correlation with biology, depth of response and survival. Br J Haematol. 2026. PMID: 42312383. doi:10.1111/bjh.70606
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。